Watertown, Mass.-based Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm with a primary focus on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its main investigational drug product candidate, ELX-02, is at the forefront of a Phase 2 clinical trial which aims to treat cystic fibrosis and nephropathic cystinosis patients who have been diagnosed with nonsense mutations. The company is also working on several preclinical programs such as alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx was founded in 2013.